Expansion at the Oval Office of the White House in Washington DC on December 7, 2020 / US President Donald Trump. Govt-19 Defense See More Stories The Trump administration is hosting a “vaccination summit” at the White House today. But any company, especially from the vaccine-centric event, will be the companies that make the vaccines – including those leading the competition for the Covid-19 vaccine, Moderna, Pfizer and Pfizer’s partner Bioendech. Companies are said to have refused or abstained, which is seen as a ploy by lame-duck President Trump. Meanwhile, senior officials in the Trump administration said the administration had decided to go “in a different direction.” The Trump administration has presented this extraordinary event as a way to educate the public on vaccine development, regulatory approval and distribution processes, and to congratulate the many veterans who helped develop the Govt-19 vaccine candidates. The event will include a “fire-side chat” with Peter Marks, the best vaccine regulator of food and drug administration. Negotiations will also take place with representatives of FedEx, UPS, Mackenzie, CVS, and Walkreens, all of whom will help get FDA-approved vaccines into the hands of the public. PR stunt But outside of the sphere of management, this event is mostly nothing more than a public relations stunt to lend Trump credit for vaccine development. It is also seen as a way to put pressure on the FDA to approve a vaccine as quickly as possible. The summit is scheduled for two days before the FDA publicly convenes an advisory panel to determine whether Pfizer and Bioentech’s COVID-19 vaccine can be given emergency use approval. According to STAT News, both Pfizer and Moderna declined invitations to attend the White House event. In response to that statement, Modernna’s spokesman clarified that the company had “expressed a desire to participate” but later decided that “its participation was not required”. In a press conference on Monday, senior Trump administration officials initially acknowledged that vaccine makers had been invited to the event. But they said they had decided to withdraw the calls after adding the FDA’s scores. Reviews with the FDA Having a vaccine regulator in the same room with pending vaccine developers could create the appearance of a conflict of interest, officials said. However, the presence of Marx as a top regulator who is not politically appointed to the FDA raises its own questions just days before the FDA makes important decisions about a Govt-19 vaccine as a key feature of such a political event. Senior executives said Monday that Marx’s involvement in the event was automatic. Pfizer Gerfiles is the latest to schedule a vaccination summit on the conflict between the Trump administration and Pfizer. Last month, both Trump and his son Donald Trump Jr. publicly recommended that Pfizer delay the release of positive vaccine test results after the presidential election in a deliberate attempt to avoid increasing Trump’s chances of re-election without evidence. Vice President Mike Pence, meanwhile, attributed the success of the Pfizer / Bioendech vaccine in part to the support of Operation Warp Speed, a federal program to help rapidly develop and distribute COVID-19 vaccines and therapies. But Pfizer quickly broke that link and distanced himself from the Trump administration. “We were never part of the warp pace … we never took money from the US government or anyone,” Katherine Johnson, executive director of Pfizer, who heads the vaccine research and development, told The New York Times. Pfizer signed a $ 1.95 billion deal with the federal government to provide 100 million doses of the vaccine — enough to vaccinate 50 million people — with the option of receiving an additional 500 million doses. But even that deal has become the center of another controversy. According to a report in The New York Times on Monday, Pfizer approached the Trump administration about locking up the deal for additional levels, but the Trump administration refused, allowing other countries to impose sanctions in advance. Now, there is concern that additional quantities will not be available in the United States until late 2021. Despite the Trump administration’s denial of the report, former FDA commissioner Scott Godlip, who is now on Pfizer’s board, reaffirmed on Tuesday that the Trump administration had denied contracts to receive additional vaccine orders. Godlip noted that there is no pre-payment required for certain contracts; If the vaccine had been approved by the FDA they would have been locked into purchase agreements instead.